Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Qiagen is expanding its next-generation sequencing portfolio of nine GeneRead DNAseq panels to about 20 during the course of this year. Qiagen is leveraging its molecular content and assay portfolio to create these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays.
Primera Technology now offers its chemical- , temperature- , and abrasion-resistant TuffCoat 2 (TC2) high-performance ink ribbons for its Signature Slide Printer. The new ribbon formulations were developed specifically to provide superior performance in pathology, histology, cytology, and other types of laboratory applications.
The FDA has approved GlaxoSmithKline’s Tafinlar (dabrafenib) and Mekinist (trametinib) oral oncology treatments. Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma or metastatic melanoma in adult patients with BRAF V600E mutation.
Milestone Medical’s BoneStation is a dedicated system for standardizing fixation and decalcification of bone specimens. Users can optimize molecular testing results with increased RNA yield from routine cases by combining less aggressive decalcifying solutions with BoneStation’s controlled agitation and temperature management.
Immunodiagnostic Systems has received FDA clearance for its 1,25-dihydroxy vitamin D assay for use on the IDS-iSys system.
The vitamin D test is used to measure 1,25-dihydroxy vitamin D deficiency, which is associated with renal disease and used in the diagnosis of disorders in the metabolism of 25-hydroxyvitamin D and phosphate.
Gold Standard Diagnostics’ new Line Immunoassay technology for Lyme confirmation testing gives clinical laboratories an FDA-cleared option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process.
Randox Laboratories and Aterovax have announced a strategic partnership to commercialize Aterovax’s secreted phospholipase A2 (sPLA2) biomarker for the assessment of cardiovascular risk.
The HardyChrom SS, from Hardy Diagnostics, is a selective chromogenic medium recommended for use as a primary screening medium for isolating and differentiating Salmonella and Shigella spp from stool cultures.
Sarstedt collection products for arterial and capillary blood gas determinations, consisting of 1-mL and 2-mL plastic blood gas syringes, contain a fine dispersion of calcium-balanced heparin, resulting in a large surface area for good solubility and quick mixing.
Dualsystems Biotech’s DualMembrane system detects novel interaction partners for membrane proteins and can be used to detect pairwise protein interactions, identify novel protein interactions by cDNA library screening, investigate ternary complexes, and map interaction domains. The system is available as a kit or custom screening service.
